Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Serum calcium levels independently predict in-hospital mortality in patients with acute myocardial infarction.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2018

Same author

Excess long-term mortality among hospital survivors of acute myocardial infarction. Soroka Acute Myocardial Infarction (SAMI) project.

Public health·2017

Same author

Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells.

Clinical and experimental immunology·2015

Same author

42 kDa Protein as a Substrate for Protein Phosphatase (s) in Intact Human Blood Platelets.

Platelets·2010

Same author

Lipoxygenase product controls the regulatory volume decrease of human platelets.

Platelets·2010

Same author

Targeting tumor-associated antigens to the MHC class I presentation pathway.

Endocrine, metabolic & immune disorders drug targets·2007

Same journal

Hexokinase controls platelet activation and hemostasis.

Platelets·2026

Same journal

Chemiluminescence resonance energy transfer-based method to investigate the platelet surface molecule in acute myocardial infarction.

Platelets·2026

Same journal

Nanobodies to GPVI as alternative reagents for platelet spreading.

Platelets·2026

Same journal

Neural network reveals platelet age from fluorescence microscopy images.

Platelets·2026

Same journal

Sixty years of research into ancestry differences in platelet function.

Platelets·2026

Same journal

Platelet-rich plasma concentrations regulate MSCs osteogenesis via MAPK/PI3K-AKT pathways to mitigate inflammatory bone loss.

Platelets·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 7, 2026

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Original article: low regulatory volume decrease rate in platelets from ischemic patients: a possible role for

A Margalit¹, H Gilutz, Y Granot

¹Department of Life Sciences, Soroka Medical Center, Faculty of the Health Sciences.

|November 4, 2010

Summary

This summary is machine-generated.

Platelet Hepoxilin-A(3) (Hx-A(3)) activity, crucial for antithrombotic function, is reduced in patients with acute ischemia. This low Hx-A(3) may impair the platelet response to shear stress.

More Related Videos

Alternative Methods for the Detection of Superoxide Anion Generation in Platelets

Alternative Methods for the Detection of Superoxide Anion Generation in Platelets

Published on: March 29, 2024

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Experiment Videos

Last Updated: Jun 7, 2026

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Alternative Methods for the Detection of Superoxide Anion Generation in Platelets

Alternative Methods for the Detection of Superoxide Anion Generation in Platelets

Published on: March 29, 2024

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Area of Science:

Biochemistry
Hematology
Cardiovascular Research

Background:

Hepoxilin-A(3) (Hx-A(3)), produced by platelets, exhibits antithrombotic properties.
Low Hx-A(3) levels are implicated in the thrombogenic state of acute coronary syndromes.
Platelet regulatory volume decrease (RVD) is modulated by Hx-A(3), suggesting RVD rate as a marker for Hx-A(3) activity.

Purpose of the Study:

To investigate platelet regulatory volume decrease (RVD) rates in patients with ischemic heart disease.
To assess the correlation between RVD rate and Hepoxilin-A(3) (Hx-A(3)) activity in various ischemic conditions.
To determine if Hx-A(3) activity is altered in patients experiencing acute ischemia.

Main Methods:

Compared RVD rates of platelets from healthy controls (n=21) with those from patients with chronic ischemic heart disease (n=23), acute ischemic heart disease (n=24), and acute myocardial infarction (MI, n=29).
Administered Hx-A(3) to platelets from MI patients to observe changes in RVD rate.
Analyzed the impact of diabetes mellitus, hypertension, and common cardiovascular medications on RVD rates.

Main Results:

Healthy controls exhibited significantly higher RVD rates than all patient groups (P < 0.001).
Addition of Hx-A(3) normalized the RVD rate in MI patients.
Patients with diabetes mellitus or hypertension showed the lowest RVD rates; aspirin, heparin, and streptokinase did not affect Hx-A(3) activity.

Conclusions:

Patients with acute ischemia may possess reduced platelet Hepoxilin-A(3) (Hx-A(3)) activity.
Diminished Hx-A(3) activity could lead to impaired antithrombotic responses to shear stress in acute ischemia.
RVD rate serves as a potential indicator of Hx-A(3) activity in ischemic heart disease.